Drug intelligence / Profile preview

MBI-101.0

Development stage: Unknown
Lead developer: Matrix Biomed
Modality: Small Molecules
Administration: Oral

Overview

MBI-101.0 is a Tempol-based small molecule developed by Matrix Biomed for the treatment of prostate cancer. It functions as an inhibitor of hypoxia-inducible factor-1 (HIF-1) and hypoxia-inducible factor-2 (HIF-2), which are master regulatory transcription factors that enable cancer cells to survive, proliferate, and adapt to the hypoxic environments typical of solid tumors. By modulating these genes, MBI-101.0 aims to suppress tumor growth and progression. The drug is part of a broader pipeline of nitroxide-based compounds (Tempol) being investigated for oncology and radiation-related indications and is currently in Phase 2 clinical development.

Targets

EPAS1 (Hypoxia-inducible factor 2-alpha)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on MBI-101.0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBI-101.0.

Explore the full profile